Learn about the mechanisms of thromboinflammation in different clinical situation with focus on the current COVID-19 outbreak and to understand the role of biomarkers to estimate diagnosis and thromboembolic risk in inflammatory disease.
Get new insights in AF and the risk of thrombotic- and bleeding- related complications and the potential use of biomarkers for AF-risk stratification.
Understand the challenges of antithrombotic management in ACS and CAD patients in order to minimize thrombotic complications and bleeding risk.
17:00 - 17:50
Welcome and Session 1: From ACS to chronic coronary artery disease. The transition period
Dirk Sibbing, Andrea Rubboli
17:52 - 18:42
Session 2: COVID-19 and thrombotic complications
18:42 - 19:27
Session 3: Atrial fibrillation and the prothrombotic state: New insights for 2021-2022
Gregory Yh Lip
Review important topics of thrombosis related with SARS-Cov-2, discuss how to improve the management of AF patients and update on the appropriate therapeutic use of antithrombotics in ACS/CAD patients